A Study of Different Doses of Grazoprevir (MK-5172) Given With Pegylated Interferon Alfa-2b and Ribavirin to Treatment-Naïve Participants With Chronic Hepatitis C (MK-5172-038)

Inclusion Criteria: * Treatment naive * Chronic, compensated HCV GT1 infection * Absence (no medical history or physical findings) of ascites, bleeding esophageal varices, hepatic encephalopathy, or other signs or symptoms of advanced liver disease, or cirrhosis * No evidence of cirrhosis or hepatocellular carcinoma by biopsy or noninvasive testing (e.g. FibroScan and/or FibroTest) * Must agree to use two acceptable methods of birth control from at least 2 weeks prior to first dose and continue until at least 6 months after last dose of study drug, or longer if dictated by local regulations Exclusion Criteria: * Non-GT1 HCV infection, including a mixed GT infection (with a non-GT1) or a non-typeable genotype. * Documented to be Human Immunodeficiency Virus (HIV) positive or co-infected with hepatitis B virus * Hepatocellular carcinoma (HCC) or under evaluation for HCC * Participating in or has participated in a study with an investigational compound or device within 30 days of signing informed consent * Diabetic and/or hypertensive with clinically significant ocular examination findings * Current or history of central nervous system trauma, seizure disorder, stroke or transient ischemic attack * Chronic pulmonary disease * Current or history of any clinically significant cardiac abnormalities/dysfunction * Active clinical gout within the last year * History of gastric surgery or history of malabsorption disorders * Active or suspected malignancy, or a history of malignancy…